Skip to content

Study · Systematic review · 2021

4 results

Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.

Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R

Alimentary pharmacology & therapeutics25 Aug 2021Cited by 81 (Europe PMC)

PMID34435378 (opens in a new tab)PMCIDPMC8711247 (opens in a new tab)DOI10.1111/apt.16583 (opens in a new tab)PepBankPUB-34435378
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of randomised trials in patients with biopsy-proven NASH, semaglutide had one of the highest probabilities of being ranked most effective for NASH resolution (SUCRA 0.89).

    In plain wordsIn a pooled comparison of trials in people with NASH, semaglutide ranked among the most likely to clear NASH (SUCRA 0.89).

    Peptide
    Semaglutide
    Outcome
    IncreaseNASH resolution rank (SUCRA)
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    0.89
    NASH resolution, semaglutide

    Source sentences

    Summary
    For NASH resolution, semaglutide, liraglutide and vitamin E plus pioglitazone had the highest probability of being ranked the most effective intervention for achieving NASH resolution (SUCRA 0.89), (SUCRA 0.84) and (SUCRA 0.83), respectively.
    2 context sentences
    Summary · context
    We included randomised controlled-trials (RCTs) comparing pharmacological interventions in patients with biopsy-proven NASH.
    Summary · context
    The secondary outcome was NASH resolution.
  2. 02HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of randomised trials in patients with biopsy-proven NASH, liraglutide had one of the highest probabilities of being ranked most effective for NASH resolution (SUCRA 0.84).

    In plain wordsIn a pooled comparison of trials in people with NASH, liraglutide ranked among the most likely to clear NASH (SUCRA 0.84).

    Peptide
    Liraglutide
    Outcome
    IncreaseNASH resolution rank (SUCRA)
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    SUCRA
    0.84
    NASH resolution, liraglutide

    Source sentences

    Summary
    For NASH resolution, semaglutide, liraglutide and vitamin E plus pioglitazone had the highest probability of being ranked the most effective intervention for achieving NASH resolution (SUCRA 0.89), (SUCRA 0.84) and (SUCRA 0.83), respectively.
    2 context sentences
    Summary · context
    We included randomised controlled-trials (RCTs) comparing pharmacological interventions in patients with biopsy-proven NASH.
    Summary · context
    The secondary outcome was NASH resolution.
  3. 03HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of randomised trials in patients with biopsy-proven NASH, semaglutide was significantly better than placebo for NASH resolution.

    In plain wordsIn a pooled comparison of trials in people with NASH, semaglutide was better than placebo at clearing NASH.

    Peptide
    Semaglutide
    Outcome
    IncreaseNASH resolution versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Conversely, semaglutide, liraglutide, vitamine E plus pioglitazone, pioglitazone, lanifibranor and obeticholic acid were significantly better than placebo in achieving NASH resolution.
    2 context sentences
    Summary · context
    We included randomised controlled-trials (RCTs) comparing pharmacological interventions in patients with biopsy-proven NASH.
    Summary · context
    The secondary outcome was NASH resolution.
  4. 04HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of randomised trials in patients with biopsy-proven NASH, liraglutide was significantly better than placebo for NASH resolution.

    In plain wordsIn a pooled comparison of trials in people with NASH, liraglutide was better than placebo at clearing NASH.

    Peptide
    Liraglutide
    Outcome
    IncreaseNASH resolution versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Conversely, semaglutide, liraglutide, vitamine E plus pioglitazone, pioglitazone, lanifibranor and obeticholic acid were significantly better than placebo in achieving NASH resolution.
    2 context sentences
    Summary · context
    We included randomised controlled-trials (RCTs) comparing pharmacological interventions in patients with biopsy-proven NASH.
    Summary · context
    The secondary outcome was NASH resolution.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.